About Us

Our Story

There is always a first.

Every major technological advancement began with the pioneers who dared to step forward, persisted in the face of challenges, and demonstrated indomitable resolve.

In 2008 Moximed recognized an opportunity that others missed. Many before described the important role of load management as a tool against knee OA, yet finally Moximed had the clear vision to design an implantable shock absorber and, through dogged persistence and resolute support from surgeons, refined and demonstrated its distinct clinical value.

A new chapter begins.

The value of a new medical product is proven through positive patient outcomes, and in 2014 Moximed introduced a platform of ISAs designed with a polymer shock absorber. The MISHA Knee System and surgical technique incorporate the knowledge and insight that can only be gained with experience and represent the highest technology that Moximed has ever developed.

The pivotal study data and patient experience validated our efforts, and we look forward to including you on the journey ahead.

Who We Are

We are trailblazers. Everyday we work to create a new beginning for patients suffering from osteoarthritis.

Christopher Gleason

President & Chief Executive Officer

Chris is an experienced medical device leader with a passion for scaling disruptive technologies and advancing patient care. With a track record of building talented, high-performing teams, Chris has recently helped create and grow sizeable businesses at Relievant (acquired by Boston Scientific) and NeoTract (acquired by Teleflex). He joined Moximed to scale the company to help knee osteoarthritis patients while advancing an exceptional company culture.

Anton Clifford, Ph.D

Founder & Chief Technology Officer

Anton had the vision to identify the clinical need and invent the solution of the implantable shock absorber. His confidence to co-found Moximed after a successful rise through small company acquisition (MedNova) and parent company (Abbott) integration, combined with his resilience and sound judgment, serve as guideposts to a growing and ascending Moximed.

Vanessa Nguyen

CHIEF FINANCIAL OFFICER

Vanessa has extensive financial, operational, and strategic experience in med tech. Her focus and passion are in leading organizations through commercial launch while building teams and the infrastructure needed to scale efficiently. Her recent experiences include executive roles at Revelle Aesthetics and NeoTract which she helped lead to successful acquisitions.

Brian Donovan

Chief Operating Officer

Brian brings seasoned product launch and commercialization experience to the expanding Moximed team. Prior to joining Moximed, Brian held Product Development and Operations leadership roles at Boston Scientific, Relievant, Medtronic, and Kyphon. His experience in scaling innovative medical devices will be pivotal in the advancement of the MISHA Knee System.

Christine Barcelos

VP People Operations

Christine’s unique ability to lead multiple, diverse functions, helped drive the success of high growth medical technology companies (Kyphon, St. Francis Medical). Her passion for recognizing and recruiting talented team members who contribute to a thriving and entrepreneurial culture is instrumental to Moximed’s growth.

Keith Fong

SVP Therapy Development and Physician Experience

Keith’s delivered consistent results for medical device stalwarts (Boston Scientific, Guidant) across multiple clinical specialties and functional roles. His nuanced understanding of Moximed’s product and market positioning, combined with an ability to develop and implement highly effective strategies and build enduring customer relationships are essential to Moximed’s success.

Michael Mydra

SVP Reimbursement and Market Access

Michael has demonstrated the ability to achieve coding, coverage, and payment for multiple innovative medical technologies. Prior to joining Moximed, Michael held reimbursement and market access leadership roles at PainTEQ, Boston Scientific and more. Michael’s experience will be instrumental as we maximize patient access for the MISHA Knee System.

Robert Spomer

SVP Sales

Robert is a master at building markets for disruptive medical technologies, having sold products and led teams at Stryker, Acclarent (acquired by JNJ), Spirox (acquired by Entellus), and Neotract (acquired by Teleflex). First-to-market is a challenge Robert embraces, and his leadership will help Moximed change the standard of care in knee OA.

Rose Weinstein

VP Clinical Affairs

Rose is a clinical research leader, bringing over 15 years of clinical expertise in Class II and III devices, while working for startups and Fortune 500 companies (J&J). Rose gravitates toward novel technologies, especially those that prioritize quality of life. Her leadership and drive to generate high-quality clinical evidence resulted in numerous regulatory approvals, publications, and favorable payer policies while at NeoTract (acquired by Teleflex) and more recently FDA market authorization of the MISHA Knee System while at Moximed.